Imiquimod and superficial skin cancers.
Topical imiquimod has opened an entirely new area of dermatology that previously did not exist: medical therapy for skin cancers. While surgery will continue to play a vital role in treating more aggressive tumors and in patients who may not be imiquimod candidates, the availability of a viable medical therapy that can be used independently or in combination with other modalities will considerably enhance our ability to treat skin cancer successfully.
Naylor
Mark
M
Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA. marknaylor@earthlink.net
D000287:Administration, Topical; D000375:Aging / Q000502:physiology; D000634:Aminoquinolines / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003357:Cosmetic Techniques; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006304:Health Status; D006801:Humans; D000077271:Imiquimod; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000191:economics* / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome
D000634:Aminoquinolines; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000077271:Imiquimod; D005472:Fluorouracil